home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

1,188 rows where filing_year = 2024 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, is_termination, received_date (date)

filing_period 4

  • third_quarter 308
  • fourth_quarter 297
  • second_quarter 294
  • first_quarter 289

issue_code 1

  • PHA · 1,188 ✖

filing_year 1

  • 2024 · 1,188 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
3138460 REPUBLIC CONSULTING, LLC e776dab9-33ed-4096-9150-37da7e408176 Q1 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2024 first_quarter PHA Monitor Health Data Policy. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-03-29T12:19:47-04:00
3138511 MCDERMOTT+ LLC d6e16179-2c50-47bb-a1ce-17d3411ef53c Q1 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2024 first_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-04-01T08:23:59-04:00
3138881 PUBLIC CITIZEN 3d77222f-f1e7-4b41-811b-90070fd8c447 Q1 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2024 first_quarter PHA march-in and other Bayh-Dole rights, Prescription Drug Affordability and Access Act, TRACK Act, Medicare drug price negotiation delay periods and exemptions; patent thicket reform, PREVAIL Act, Affordable and Safe Prescription Drug Importation Act, HR5539/S3131 ORPHAN Cures Act; HR5547/S476 Maintaining Investments in New Innovation Act; HR7174, PASTEUR Act, patent thicket reform, biosimilar interchangeability; Medicare drug price negotiation delay periods, expansion to commercial market, march-in and other licensing rights; Pandemic Accord access provisions, Prescription Drug Affordability and Access Act, Pandemic Accord access provisions; public pharmaceutical manufacturing. Commerce, Dept of (DOC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   88000 0 0 2024-04-02T10:46:25-04:00
3138975 AMERICAN COLLEGE OF CLINICAL PHARMACY e7423c4b-9da7-41ca-8098-5280709b1e59 Q1 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2024 first_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2024-04-02T13:50:47-04:00
3139635 WAKEFERN FOOD CORP. 256b7be2-37f2-44b9-a84a-deecf53308c5 Q1 WAKEFERN FOOD CORP. 400588798 WAKEFERN FOOD CORP. 2024 first_quarter PHA Comprehensive pharmacy benefit manager (PBM)/DIR fee reform H.R. 5378 - "Lower Costs, More Transparency Act" S. 3430 - "Better Mental Health Care, Lower-Cost Drugs, and Extenders Act" S. 2973 - "Modernizing and Ensuring PBM Accountability Act" Legislative measures add more transparency HOUSE OF REPRESENTATIVES,SENATE     0 0 2024-04-04T09:45:30-04:00
3140244 PENN AVENUE PARTNERS 7473185f-c2aa-41ab-83b9-ec794e9945c8 Q1 PENN AVENUE PARTNERS 400918672 ALKERMES, INC. 2024 first_quarter PHA Regulatory and legislative issues impacting Alkermes. Appropriations. H.R.5894 - Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-04-07T06:39:39-04:00
3140278 PENN AVENUE PARTNERS e81518cd-18bc-469d-a475-d786e32429b4 Q1 PENN AVENUE PARTNERS 400918672 UNITEDHEALTH GROUP, INC. 2024 first_quarter PHA Pharmacy benefit related issues. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office 90000   0 0 2024-04-07T08:44:48-04:00
3140282 4C COMMUNICATIONS, INC. af20bc70-898e-4fb2-8815-3a0fa93dac44 Q1 4C COMMUNICATIONS, INC. 323717 HEALTHCARE LEADERSHIP COUNCIL 2024 first_quarter PHA H.R. 7050, Substance Use Disorder Workforce Act H.R. 7312, Electronic Prescribing for Controlled Substances 2.0 Act S. 2666, Electronic Prescribing for Controlled Substances Act HOUSE OF REPRESENTATIVES,SENATE     0 0 2024-04-07T10:41:53-04:00
3140325 RED+BLUE STRATEGIES 8715751c-4ff5-418f-bba5-b1eda1676b60 Q1 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2024 first_quarter PHA H.R. 4366 - Consolidated Appropriations Act of FY 2024 - Issues related to health care policy provisions included in the bill writ large. H.R. 2882 - Further Consolidated Appropriations Act of FY 2024 - Issues related to funding of the Department of Health and Human Services and agencies governing programs dedicated to the coverage of prescription medications. S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees. S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients. H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare. S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications. S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission. S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest. Issues related to prescription drug supply chain integrity and transparency. Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to… Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2024-04-07T16:52:55-04:00
3140399 HOLLAND & KNIGHT LLP 500465c7-b868-4d11-845d-02342ef590cb Q1 HOLLAND & KNIGHT LLP 18466 VIATRIS INC 2024 first_quarter PHA Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-04-08T09:50:20-04:00
3140447 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 36439ef0-3f60-486e-ba63-f42ad67ffeab Q1 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 11003 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 2024 first_quarter PHA CCAGW Urges House Oversight Committee to Oppose H.R. 6283 HOUSE OF REPRESENTATIVES   360000 0 0 2024-04-08T10:35:42-04:00
3140700 KOUNTOUPES DENHAM CARR & REID, LLC 147ac877-8cbc-47e7-928d-aec040efb936 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ABBOTT LABORATORIES 2024 first_quarter PHA Legislation to expand Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S.2477, the Equitable Community Access to Pharmacist Services Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-04-08T16:26:05-04:00
3140764 2359 STRATEGIES 9901c974-9530-4210-a8ee-c8a75fc674da Q1 2359 STRATEGIES 401106114 TRAVERE THERAPEUTICS 2024 first_quarter PHA Orphan Drug Act HOUSE OF REPRESENTATIVES,SENATE 12000   0 0 2024-04-08T20:03:07-04:00
3141001 EMERGENT STRATEGIES 5b18d3e0-5096-4166-82b7-9eb5a78e7321 Q1 EMERGENT STRATEGIES 401104778 GENBIOPRO, INC. 2024 first_quarter PHA FDA Approval of generic mifepristone and related Risk Evaluation Mitigation Strategies (REMS). HOUSE OF REPRESENTATIVES,SENATE 35000   0 0 2024-04-09T11:44:30-04:00
3141108 MASON STREET CONSULTING, LLC f89973b0-d06d-43cb-84cd-ab112b6802a5 Q1 MASON STREET CONSULTING, LLC 401105150 CAPITAL RX INC. 2024 first_quarter PHA PBM Reform. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-04-09T14:26:32-04:00
3141127 KOUNTOUPES DENHAM CARR & REID, LLC da292256-322c-43f3-8e90-c1f0b26d012c Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2024 first_quarter PHA Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. Issues related to drug pricing transparency. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S. 2477, The Equitable Community Access to Pharmacist Services Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-04-09T15:42:49-04:00
3141140 KOUNTOUPES DENHAM CARR & REID, LLC e7e593da-3331-4b25-b5af-14b5a1cb1e5d Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2024 first_quarter PHA General issues related to Over-The-Counter (OTC) pharmaceutical supply chain. Issues related to Drug Enforcement Administration Pseudoephedrine quotas. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-04-09T16:01:29-04:00
3141147 KOUNTOUPES DENHAM CARR & REID, LLC c21cbecf-abf6-479a-bf9e-e7bfd7f7b871 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2024 first_quarter PHA Issues related to drug pricing transparency. Issues related to pharmacy benefit managers. Issues related to testing, vaccination and treatment including H.R. 1770 and S. 2477, the Equitable Community Access to Pharmacist Services Act. Issues related to prescription drug access and affordability. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-04-09T16:10:39-04:00
3141240 TRUSYNERGY 15b7ee53-2dfb-418e-b789-4168ada80f23 Q1 TRUSYNERGY 401107715 BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.) 2024 first_quarter PHA Oversight of the Strategic National Stockpile to promote safer and more effective treatments in the stockpile; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; FY 24 LHHS appropriations; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; increasing domestic manufacturing and onshoring of treatments and their components; BARDA funding and oversight; IBMSC funding and oversight; FY 25 LHHS appropriations; MCM PRV HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2024-04-10T06:25:33-04:00
3141684 DAVE KOLBE CONSULTING 1aa2128d-aa21-472e-b1c9-90a0bbf94ade Q1 DAVE KOLBE CONSULTING 401104329 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2024 first_quarter PHA Negative Impacts of Expanding TRIPS - Strongly oppose expanding the TRIPS Waiver as it would endanger American Jobs without improving global health. H.R. 6283 DRUG-ACT - Request to co-sponsor the Drug-Act, vote to move to markup in committee and include in the next spending bill. MARCH-IN Congressional Letter - Asking Congressional Members to sign on to letter to President Biden opposing the recent NIST guidance. Proposed guidance attempts to change the landmark Bayh-Dole Act without the consent of Congress. The draft framework will hamstring U.S. innovation to the advantage of competitors and adversaries. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-04-10T20:30:44-04:00
3142371 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) b9579401-f3ff-469c-8c14-ef9270157af6 Q1 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2024 first_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-04-12T10:22:07-04:00
3142760 INDEPENDENT PHARMACY COOPERATIVE f356a8c3-e2e5-4f7e-b5eb-93ddc31fa066 Q1 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2024 first_quarter PHA IPC supports Drug Transparency in Medicaid Act (H.R. 1613) ICP supports Promoting Access to Treatments and Increasing Extremely Needed Transparent (PATIENT) Act (HR 3561) IPC supports Drug Transparency in Medicaid Act (S. 1038) IPC supports The Modernizing and Ensuring PBM Accountability Act (S 2973) IPC supports Pharmacy and Medically Underserved Areas Enhancement Act (S 1491) IPC supports Protecting Patients Access to Pharmacy Act (S. 2052) IPC supports The Health Care Price Transparency Act (H.R. 4822) IPC supports Lower Cost, More Transparency Act (LCMT) (H.R. 5378) IPC supports Protecting Patients Against PBM Abuses Act (H.R. 2880) IPC Transparency and Fairness for Pharmacies Act (H.R. 5393) IPC supports Senate Bi-Partisan Working Group for 340B Reform - RFI response. IPC Supports FDA - Development of Small Dispensers Assessment Under the Drug Supply Chain Security Act; Request for Comments (FDA-2023-N-3103) IPC supports the Inflation Reduction Act of 2022 and CMS implementation. IPC opposes S. 1339 Pharmacy Benefits Reform Act - because it may preempt state PBM laws relating to ERISA. IPC supports S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act IPC supports S. 127 Pharmacy Benefit Manager Transparency Act IPC supports (H.R. 1770/S. 2477) The Equitable Community Access to Pharmacists Services Act CMS Implementation of PY 2024 Medicare Part D drug rule CMS Implementation of drug provisions of the IRA 2022. Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE   130000 0 0 2024-04-12T14:20:59-04:00
3142850 PANNONE LOPES DEVEREAUX & O'GARA LLC 1cfb5183-d465-476b-888a-6ffaac3035dd Q1 PANNONE LOPES DEVEREAUX & O'GARA LLC 401105501 AMGEN 2024 first_quarter PHA Prescription drug pricing.   9000   0 0 2024-04-12T15:42:59-04:00
3142889 DENTONS US LLP ff3ff60e-3462-43b2-b6ab-46df946bdc65 Q1 DENTONS US LLP 36105 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA 2024 first_quarter PHA Federal issues impacting workforce and innovation in the pharmaceutical industry. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-04-12T16:02:06-04:00
3143269 FORBES-TATE e353961c-d642-43c7-b862-dae7cda04fca Q1 FORBES-TATE 400976792 CALIFORNIA LIFE SCIENCES ASSOCIATION 2024 first_quarter PHA Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-04-12T19:30:12-04:00
3143420 KING & SPALDING LLP 8fd3d1cb-eeb9-455d-a076-2d984386d4bb 1T KING & SPALDING LLP 21632 SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.) 2024 first_quarter PHA Advocacy on low income subsidy benefits HOUSE OF REPRESENTATIVES,SENATE 60000   0 1 2024-04-12T21:25:44-04:00
3143450 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 1b9ee0db-1be8-4495-a398-984eb3f8c550 Q1 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2024 first_quarter PHA 340B, Hospital at Home Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   35600 0 0 2024-04-13T09:16:53-04:00
3143746 FORBES-TATE 7fbcf3d8-414f-452e-858a-3c854617d216 Q1 FORBES-TATE 400976792 PHRMA 2024 first_quarter PHA Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2024-04-13T22:50:39-04:00
3143833 FORBES-TATE 3bb84907-976c-43f8-a7f8-76dc59156607 Q1 FORBES-TATE 400976792 INDEPENDENT PHARMACY COOPERATIVE 2024 first_quarter PHA Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-04-14T11:29:33-04:00
3144490 AMERICAN VETERINARY MEDICAL ASSOCIATION 115a181f-3c88-4a90-9fe7-e928f171f636 Q1 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2024 first_quarter PHA H.R. 1839/S. 993 Combatting Illicit Xylazine Act H.R. 4531 SUPPORT Act S. 3393 SUPPORT for patients and Communities Reauthorization Act, review of language related to xylazine for potential inclusion Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE   380000 0 0 2024-04-15T09:55:55-04:00
3145044 AMERICAN SOCIETY OF CONSULTANT PHARMACISTS 915d4b15-2fad-486e-af7e-e4a47b83816e Q1 AMERICAN SOCIETY OF CONSULTANT PHARMACISTS 3446 AMERICAN SOCIETY OF CONSULTANT PHARMACISTS 2024 first_quarter PHA HR 1770 - Provider status legislation for pharmacists Access to long-term care pharmacy services for home-based patients Access to vaccines for long-term care residents Cybersecurity attack on Change Healthcare Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   15000 0 0 2024-04-15T13:55:30-04:00
3145146 THE CONSILIO GROUP 4dd0ce12-2af7-43ec-a5be-3e1ba6939b4f Q1 THE CONSILIO GROUP 400374717 PARATEK PHARMACEUTICALS 2024 first_quarter PHA Development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office 36000   0 0 2024-04-15T14:35:16-04:00
3145327 FOLEY & LARDNER LLP 1756a548-dd6f-467e-bb17-f65475003b29 Q1 FOLEY & LARDNER LLP 15042 ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY 2024 first_quarter PHA Issues related to implementation of the Inflation Reduction Act and the Bipartisan Infrastructure Bill; Issues related to supply chain resilience. HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2024-04-15T15:47:13-04:00
3145686 BROWNSTEIN HYATT FARBER SCHRECK, LLP 406e049f-c018-4468-86ea-c2d8185c0e13 Q1 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 WALGREEN CO. 2024 first_quarter PHA Pharmacist provider status Issues related to drug pricing Issues related to access and distribution of pharmaceutical products Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES 50000   0 0 2024-04-15T17:54:39-04:00
3146235 WAXMAN STRATEGIES 2d974d90-8318-4175-9d1d-7bc588fe97f3 Q1 WAXMAN STRATEGIES 401103693 340B HEALTH 2024 first_quarter PHA Issues affecting the 340B drug pricing program; Appropriations for 340B program. HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2024-04-16T11:50:32-04:00
3146272 THE MATHIS HARPLE GROUP 20019fbf-4bdf-415b-a2cb-3a837e92f579 Q1 THE MATHIS HARPLE GROUP 322911 PHRMA 2024 first_quarter PHA Price Controls, Intellectual Property Rights S.127 S.113 S.1339 HOUSE OF REPRESENTATIVES,SENATE     0 0 2024-04-16T11:54:41-04:00
3146448 THE MATHIS HARPLE GROUP 2a852fa2-51e0-4a8f-b68e-2f6a764ca885 Q1 THE MATHIS HARPLE GROUP 322911 PILMA 2024 first_quarter PHA Price Controls, Intellectual Property Rights S.127, S.113, S.1339 HOUSE OF REPRESENTATIVES,SENATE     0 0 2024-04-16T13:01:55-04:00
3146702 TARPLIN, DOWNS & YOUNG, LLC 73fcd0e8-2377-4cb0-b098-220b2edc0ccd Q1 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2024 first_quarter PHA Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA) Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 80000   0 0 2024-04-16T14:29:08-04:00
3147110 60 PLUS ASSOCIATION b56ca7fd-a7cb-4f5f-9ef9-e1bb3d55560c Q1 60 PLUS ASSOCIATION 41988 60 PLUS ASSOCIATION 2024 first_quarter PHA Urging Members of Congress and the Biden Administration to support and advance the Equitable Community Access to Pharmacist Services Act (H.R. 1770, S. 2477) to provide payment for essential pharmacist services under Medicare Part B and ensure pharmacists can continue to protect seniors from the threat of COVID-19, influenza, RSV, strep throat, pneumococcal, and hepatitis B. HOUSE OF REPRESENTATIVES,SENATE,White House Office     0 0 2024-04-16T15:48:29-04:00
3147196 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 4498e81b-e77e-4098-a2f9-db4f64bb5e8b Q1 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2024 first_quarter PHA OTC Switch - general advocacy on Prescription to Over-the-Counter Switch of medications and ingredients. Proposed rule for Nonprescription Drug Product with an Additional Condition for Nonprescription Use H.R. 2964/S. 1350 - The Wastewater Infrastructure Pollution Prevention and Environmental Safety Act or the WIPPES Act FDA Nonprescription Drugs Advisory Committee Meeting on Phenylephrine Activities related to Over-the-Counter Monograph Drug User Fee Drug Enforcement Administration Pseudoephedrine quotas Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 168788   0 0 2024-04-16T16:06:57-04:00
3147652 AARP c4513bc0-c173-49a5-ab85-9d1002b1f8b2 Q1 AARP 1694 AARP 2024 first_quarter PHA No bill number. Discussed the Medicare Prescription Payment Plan program. H.R. 5385, the Medicare PBM Accountability Act. H.R. 5372, Expanding Seniors Access to Lower Cost Medicines Act of 2023. H.R. 2880, Protecting Patients Against PBM Abuses Act. H.R. 5539, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act. H.R. 5547, the Maintaining Investments in New Innovation (MINI) Act. S. 79, the Interagency Patent Coordination and Improvement Act of 2023. S. 150, the Affordable Prescriptions for Patients Act of 2023. S. 113, the Prescription Pricing for the People Act of 2023. S. 142, the Preserve Access to Affordable Generics and Biosimilars Act. S. 148, the Stop STALLING Act. No bill number. Discussed the Reducing Drug Prices for Seniors Act. No bill number. Discussed the Inflation Reduction Act. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   4370000 0 0 2024-04-17T08:46:01-04:00
3147795 DESIMONE CONSULTING, LLC 5f4c5e39-6f5a-4c62-aa16-5b0ff5b682a3 Q1 DESIMONE CONSULTING, LLC 400931695 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) 2024 first_quarter PHA Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to PBM reform; H.R. 2880, Protecting Patients Against PBM Abuses Act and H.R.5376, Share the Savings with Seniors Act. Issues related to 340B reform. Issues related to the Ensuring Pathways to Innovative Cures (EPIC) Act, H.R.7174. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-04-17T09:56:07-04:00
3148721 HARMONY BIOSCIENCES f40e73db-3678-4df8-a6e0-e57ac83a50ec Q1 HARMONY BIOSCIENCES 401105020 HARMONY BIOSCIENCES 2024 first_quarter PHA Issues related to the development and approval of rare disease treatments HOUSE OF REPRESENTATIVES,SENATE   170000 0 0 2024-04-17T13:19:52-04:00
3148950 PRIME POLICY GROUP 8df2c3e4-f569-4797-9ab7-de79c838732d Q1 PRIME POLICY GROUP 400532589 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2024 first_quarter PHA H.R.1770 - Equitable Community Access to Pharmacist Services Act; PBM reform; S.2666 - EPCS 2.0 Act HOUSE OF REPRESENTATIVES,SENATE,White House Office 80000   0 0 2024-04-17T14:04:29-04:00
3149011 MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) d68658e4-c51d-4820-8818-13c7864ad188 Q1 MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) 24566 MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS 2024 first_quarter PHA H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   1580000 0 0 2024-04-17T14:22:13-04:00
3149296 NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) 3083ee6c-ff9d-437b-bbf6-f9f304d35c64 Q1 NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) 28264 NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) 2024 first_quarter PHA Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. Rare Pediatric Disease Priority Review Vouchers (RDP-PRV). Pediatric Study Requirements. Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   60000 0 0 2024-04-17T15:26:00-04:00
3149555 DA VINCI GROUP b2842b8e-006d-43d5-a62a-4c1bed844934 Q1 DA VINCI GROUP 11548 BOESEN & SNOW, LLC 2024 first_quarter PHA Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2024-04-17T16:35:27-04:00
3149676 PRIME POLICY GROUP eefc694f-26a8-4aab-8890-499ba400d634 Q1 PRIME POLICY GROUP 400532589 QUVA PHARMA, INC. 2024 first_quarter PHA Legislation and regulation impacting outsourcing facilities regulated under Section 503B under the Federal Food, Drug, and Cosmetic Act HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-04-17T17:09:35-04:00
3149840 CORNERSTONE GOVERNMENT AFFAIRS, INC. df9d2982-03b5-4910-b374-b1616d8f5acc Q1 CORNERSTONE GOVERNMENT AFFAIRS, INC. 75557 CHILDREN'S NATIONAL MEDICAL CENTER 2024 first_quarter PHA Health-related issues including reimbursement, research, public-health & clinical care. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2024-04-17T18:03:43-04:00
3149867 ARENTFOX SCHIFF LLP 46b22b57-2edd-4328-ac69-870893542e76 Q1 ARENTFOX SCHIFF LLP 4208 AMERICAN PHARMACY COOPERATIVE, INC. 2024 first_quarter PHA Prescription drug pricing generally Pharmacy Benefit Manager (PBM) reform generally S. 2973 (Modernizing and Ensuring PBM Accountability Act), all provisions S. 1339 (Pharmacy Benefit Manager Reform Act), regarding Pharmacy Benefit Manager (PBM) reform S. 3430 (Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023), regarding Pharmacy Benefit Manager (PBM) reform H.R. 5378 (Lower Costs, More Transparency Act), regarding Pharmacy Benefit Manager (PBM) reform H.R. 6283 (DRUG Act), regarding Pharmacy Benefit Manager (PBM) reform HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-04-17T18:13:07-04:00
3149880 BLUE SHIELD OF CALIFORNIA dab653d7-c17c-437c-9c88-562ca416d481 Q1 BLUE SHIELD OF CALIFORNIA 6518 BLUE SHIELD OF CALIFORNIA 2024 first_quarter PHA H.R.5378 - Lower Costs, More Transparency Act; provisions related to pharmacy benefit managers. HOUSE OF REPRESENTATIVES,SENATE   110000 0 0 2024-04-17T18:17:57-04:00
3149915 PORT SIDE STRATEGIES, LLC a9671007-67f6-4f23-8545-145b17519189 Q1 PORT SIDE STRATEGIES, LLC 401105394 SOCIAL SECURITY WORKS 2024 first_quarter PHA Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-04-17T18:42:40-04:00
3149921 PORT SIDE STRATEGIES, LLC 66035456-9c6f-4f6a-9456-13831f8e6be8 Q1 PORT SIDE STRATEGIES, LLC 401105394 NEW VENTURE FUND 2024 first_quarter PHA Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. H.R.4895 - Lowering Drug Costs for American Families Act - in support. H.R.485 - Protecting Health Care for All Patients Act of 2023 - opposed. HOUSE OF REPRESENTATIVES,SENATE     0 0 2024-04-17T18:44:11-04:00
3149935 PORT SIDE STRATEGIES, LLC 1576d727-dc13-41d3-a0cb-1c8ab3bba27a Q1 PORT SIDE STRATEGIES, LLC 401105394 CENTER FOR HEALTH AND DEMOCRACY 2024 first_quarter PHA Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. H.R.5378 - Lower Costs, More Transparency Act - in support. S.2973 - Modernizing and Ensuring PBM Accountability Act - in support. Issues related to expanding out-of-pockets costs. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 20000   0 0 2024-04-17T18:45:49-04:00
3150471 BROWNSTEIN HYATT FARBER SCHRECK, LLP 5be60241-4551-4b9c-89ad-fb9c6790e81d Q1 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 LILLY USA, LLC 2024 first_quarter PHA Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation H.R. 4818 Treat and Reduce Obesity Act HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2024-04-18T10:31:55-04:00
3150622 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. fc95e1de-79e3-467d-aa9e-fc7c2beef1b0 Q1 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 6382 BLUE CROSS AND BLUE SHIELD OF FLORIDA INC 2024 first_quarter PHA COVID Therapeutics; Cell and Gene Therapy; Step Therapy HR 5372 (118th Congress), Expanding Seniors' Access to Lower Cost Medicines Act of 2023, by Rep. John Joyce (R-PA). To amend Title XVIII of the Social Security Act to facilitate midyear formulary changes for biosimilars. HR 5376 (117th Congress), Inflation Reduction Act of 2022, by Rep. John Yarmuth (D-KY). Requires the Centers for Medicare & Medicaid Services (CMS) to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. HR 7312 (118th Congress), EPCS 2.0 Act, by Rep. Ann Kuster (D-NH). To provide requirements for electronic prescribing for controlled substances under group health plans and group and individual health insurance coverage. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   210000 0 0 2024-04-18T11:01:27-04:00
3150662 GUIDEWELL MUTUAL HOLDING CORPORATION b39805a9-1ccd-4226-a379-bb23c061e710 Q1 GUIDEWELL MUTUAL HOLDING CORPORATION 401103191 GUIDEWELL MUTUAL HOLDING CORPORATION 2024 first_quarter PHA COVID Therapeutics; Cell and Gene Therapy; Step Therapy HR 5372 (118th Congress), Expanding Seniors' Access to Lower Cost Medicines Act of 2023, by Rep. John Joyce (R-PA). To amend Title XVIII of the Social Security Act to facilitate midyear formulary changes for biosimilars. HR 5376 (117th Congress), Inflation Reduction Act of 2022, by Rep. John Yarmuth (D-KY). Requires the Centers for Medicare & Medicaid Services (CMS) to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. HR 7312 (118th Congress), EPCS 2.0 Act, by Rep. Ann Kuster (D-NH). To provide requirements for electronic prescribing for controlled substances under group health plans and group and individual health insurance coverage. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   10000 0 0 2024-04-18T11:05:55-04:00
3150702 BUCHANAN INGERSOLL & ROONEY PC 4ad2699d-ed97-4a64-b1a6-efb1bff1a914 Q1 BUCHANAN INGERSOLL & ROONEY PC 55291 AIM IMMUNOTECH INC. 2024 first_quarter PHA Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-04-18T11:11:25-04:00
3150740 AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION c2302ec3-5f68-4b81-9d72-3eafe7abe468 Q1 AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION 1331 AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION 2024 first_quarter PHA Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Support S. 127, Pharmacy Benefit Manager Transparency Act Support H.R. 830/ S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2630/S. 652, Safe Step Act. Support H.R. 167, Patient Access to Urgent-Use Pharmacy Compounding Act Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   700000 0 0 2024-04-18T11:24:09-04:00
3150788 BUCHANAN INGERSOLL & ROONEY PC 72522a53-10c5-49d5-9263-000060cd32f4 Q1 BUCHANAN INGERSOLL & ROONEY PC 55291 GENERIC ANIMAL DRUG ALLIANCE 2024 first_quarter PHA Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-04-18T11:37:51-04:00
3150824 NATIONAL RURAL LETTER CARRIERS' ASSOCIATION 84ace21e-e71b-4f9e-82b8-63828f6dc4f3 Q1 NATIONAL RURAL LETTER CARRIERS' ASSOCIATION 28526 NATIONAL RURAL LETTER CARRIERS' ASSOCIATION 2024 first_quarter PHA H.R. 6283,"DRUG Act"- legislation that impacts Pharmacy Benefit Managers (PBMs), it could have the unintended consequences of reducing mail volume and increasing the costs/premiums of employer sponsored health programs. The NRLCA has not taken a position on this legislation. S. 1542, "DRUG Act"- Senate companion bill to H.R. 6283, the NRLCA has not taken a position on this bill. HOUSE OF REPRESENTATIVES,SENATE   125000 0 0 2024-04-18T11:44:27-04:00
3150956 BROWNSTEIN HYATT FARBER SCHRECK, LLP 391d599e-9288-41ec-9123-491a93f51c79 Q1 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 CENCORA, INC. 2024 first_quarter PHA Recognizing pharmacists as providers within Medicare; The Equitable Community Access to Pharmacist Services Act (H.R.1770/S. 2477; Medicare reimbursement. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-04-18T12:08:03-04:00
3150969 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 6e1300ad-2a82-474f-b9cd-4065f8ef7558 Q1 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2024 first_quarter PHA Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The PROTECT 340B Act (H.R. 2534) and the 340B Pharmaceutical Access to Invest in Essential, Needed Treatments & Support Act of 2024 (H.R. 7635), provisions related to enforcement of the 340B Drug Pricing Program. Issues related to pharmacy residency funding (generally, no specific legislation). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to authorization of technician product verification (generally, no specific legislation). The Biosimilar Red Tape Elimination Act (S. 2305), issues related to accelerating biosimilar adoption. Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   240000 0 0 2024-04-18T12:11:57-04:00
3151005 SEWARD SQUARE GROUP 090d5a50-d0b9-4337-9056-ba14ccec9471 Q1 SEWARD SQUARE GROUP 400478356 RITE AID CORPORATION 2024 first_quarter PHA Advised on the Equitable Community Access to Pharmacist Services Act is a PBM reform bill. Health & Human Services, Dept of (HHS) 50000   0 0 2024-04-18T12:24:27-04:00
3151145 BLUECROSS BLUESHIELD OF TENNESSEE a5a0e9c6-2814-4c48-b9ea-c98d25f6b656 Q1 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2024 first_quarter PHA Prescription Drug Pricing Reform; Pharmacy Benefit Managers; Delinking PBM language S. 1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage HOUSE OF REPRESENTATIVES,SENATE   200000 0 0 2024-04-18T12:53:03-04:00
3151264 OREGON HEALTH & SCIENCE UNIVERSITY d91155cc-b766-47ce-856c-21572f853601 Q1 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2024 first_quarter PHA Support for 340B Drug Discount Program and resulting patient and community benefits provided through participating safety-net hospitals and other covered entities; opposition to imposing administrative burden to the program through new mandatory reporting requirements beyond regular HRSA audits, and policy limiting the scope and drug discounts provided under of the program; and support for Congressional and/or Administration action to prohibit pharmaceutical manufacturer denials of 340B drug discounts to safety-net hospitals and other 340B covered entities. HOUSE OF REPRESENTATIVES,SENATE   60000 0 0 2024-04-18T13:10:23-04:00
3151616 BURRELL INTERNATIONAL GROUP LLC 1ddacf6a-e814-4915-9edb-62bc19c2e2a9 Q1 BURRELL INTERNATIONAL GROUP LLC 401103483 TONIX PHARMACEUTICALS HOLDING CORP. 2024 first_quarter PHA LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-04-18T13:49:26-04:00
3151628 BURRELL INTERNATIONAL GROUP LLC ddb5bf88-be2c-467c-ad9e-0c5d036ee3d9 Q1 BURRELL INTERNATIONAL GROUP LLC 401103483 SHIONOGI INC. 2024 first_quarter PHA Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023 HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-04-18T13:50:18-04:00
3151649 MASSACHUSETTS MEDICAL SOCIETY 095d57d4-9b9d-4c0f-88f4-c9111a65c5a8 Q1 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2024 first_quarter PHA Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill S. 470/HR 977, The Patient Access to Higher Quality Health Care Act HOUSE OF REPRESENTATIVES,SENATE   60000 0 0 2024-04-18T13:51:38-04:00
3151790 ELI LILLY AND COMPANY 197d75a7-652d-4829-b7c4-e70e656ed971 Q1 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2024 first_quarter PHA Hospital discounts; 340B program HOUSE OF REPRESENTATIVES,SENATE   1730000 0 0 2024-04-18T14:10:16-04:00
3151811 SHIONOGI INC. e07c90c1-78bb-466a-baf8-ff14938b0a52 Q1 SHIONOGI INC. 401107081 SHIONOGI INC. 2024 first_quarter PHA Pandemic preparedness; Antimicrobial resistance; Pandemic and All Hazards Preparedness Act (PAHPA) Reauthorization; PASTEUR Act (H.R. 2940, S. 1355) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   120000 0 0 2024-04-18T14:15:25-04:00
3151834 BURRELL INTERNATIONAL GROUP LLC cb2c6ec7-2e7b-41f1-9586-c78e766664d9 1A BURRELL INTERNATIONAL GROUP LLC 401103483 SHIONOGI INC. 2024 first_quarter PHA FY25 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Priority Review Voucher and MCM Development funding HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-04-18T14:20:39-04:00
3151850 BURRELL INTERNATIONAL GROUP LLC 0f41f0e8-b64e-412d-a673-f960ef3662b7 1A BURRELL INTERNATIONAL GROUP LLC 401103483 TONIX PHARMACEUTICALS HOLDING CORP. 2024 first_quarter PHA LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY25 Defense Appropriation for broad-spectrum antivirals, FY25 LHHS for long covid and cocaine overdose funding HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-04-18T14:22:46-04:00
3152060 GOVERNMENT COUNSEL, LLC 1a505080-2c8c-4068-ba9b-98f85ce6d1c3 Q1 GOVERNMENT COUNSEL, LLC 401105070 HEALTHCARE DISTRIBUTION ALLIANCE 2024 first_quarter PHA Issues relating to the prevention and mitigation of pharmaceutical shortages. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-04-18T14:49:10-04:00
3152142 E3 STRATEGIC CONSULTING GROUP 79424a12-af50-470d-8b62-fa880536070a Q1 E3 STRATEGIC CONSULTING GROUP 401104104 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2024 first_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023; H.R.830 - HELP Copays Act; S. 1542 - Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act"); HR 4895 - H.R. 4895: Lowering Drug Costs for American Families Act; H.R. 2880: Protecting Patients Against PBM Abuses Act; HR 6283 - The Drug Act; HR 5378 - Lower Costs, More Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-04-18T14:55:23-04:00
3152161 BRAVO GROUP 1b55dae8-b511-4b9c-912b-8ebf79bcea38 Q1 BRAVO GROUP 296293 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2024 first_quarter PHA Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-04-18T14:56:57-04:00
3152224 HANCE SCARBOROUGH ce519119-c1f9-463a-bd0b-d10edfca554c Q1 HANCE SCARBOROUGH 17443 ALLIANCE FOR PHARMACY COMPOUNDING 2024 first_quarter PHA Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2025 Appropriations HR167, the Patient Access to Urgent Use Compounded Medication Act HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-04-18T15:07:43-04:00
3152370 FROST BROWN TODD LLC 21294716-540c-482f-98ff-53050b2ad67c Q1 FROST BROWN TODD LLC 283572 DISPOSERX 2024 first_quarter PHA Support Act Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-04-18T15:29:17-04:00
3152418 UNIVERSITY OF IOWA 3d23fdd9-b153-4038-ba9a-3cc5e870ba53 Q1 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2024 first_quarter PHA N/A HOUSE OF REPRESENTATIVES,SENATE   90000 0 0 2024-04-18T15:35:24-04:00
3152453 ISEMAN & ASSOCIATES LLC b3e91923-9073-45a2-92b1-120cc9082cec 1A ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2024 first_quarter PHA Monitoring biotech legislation; prescription drug prices; Infrastructure Legislation HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2024-04-18T15:40:34-04:00
3152466 HB STRATEGIES d22a485a-3b69-477b-b25a-17a86f91ccbb Q1 HB STRATEGIES 401104718 BAYER U.S. LLC 2024 first_quarter PHA Provide lobbying support of key issues and track relevant federal policy developments that could impact the pharmaceutical, healthcare and agricultural industries generally and Bayer specifically. HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2024-04-18T15:46:16-04:00
3152608 HANCE SCARBOROUGH 9a16d9f7-602b-4720-8c04-7af0ed176d73 Q1 HANCE SCARBOROUGH 17443 BOEHRINGER INGELHEIM USA CORPORATION 2024 first_quarter PHA Provide ongoing animal health policy monitoring, assessment, and research support. Farm Bill. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-04-18T16:18:36-04:00
3152768 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH df659c99-dec7-4646-a0dc-2100ac4e3869 Q1 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 401104060 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 2024 first_quarter PHA Lobbying to improve prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led an digital campaign to allow constituents to write their members of Congress in support of this legislation. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2024-04-18T17:02:21-04:00
3152817 COREWELL HEALTH 55749dda-cc46-4dad-90a3-b60e0126a53f Q1 COREWELL HEALTH 298455 COREWELL HEALTH 2024 first_quarter PHA 340B PBM Reform/Oversight Regulation of controlled substances via telehealth prescribing practices Transparency and high costs associated with prescription drugs Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE   180000 0 0 2024-04-18T17:17:19-04:00
3153370 MARSHALL & POPP, LLC 8c2e1310-723f-4fdf-82b1-4db9f0e34cc9 Q1 MARSHALL & POPP, LLC 401105121 ABBVIE INC. 2024 first_quarter PHA Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-04-18T23:57:56-04:00
3153376 MARSHALL & POPP, LLC 6330d448-c4b9-4614-8c04-e0b4b25f293e Q1 MARSHALL & POPP, LLC 401105121 AMGEN USA INC. 2024 first_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act, and H.R. 4366, Consolidated Appropriations Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. S.Res. 496 and S.Res.566 - National Cholesterol Education Month. S. 3558, Biosecure. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-04-19T00:06:31-04:00
3153389 MARSHALL & POPP, LLC 0b3f603b-f368-4f77-861a-e90fa3229117 Q1 MARSHALL & POPP, LLC 401105121 GENENTECH, INC. 2024 first_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act, and H.R. 4366, Consolidated Appropriations Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-04-19T00:24:46-04:00
3153403 MARSHALL & POPP, LLC 7a7e74ae-c7e0-45b6-a19d-56b63d82a3a6 Q1 MARSHALL & POPP, LLC 401105121 PFIZER, INC. 2024 first_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act, and H.R. 4366, Consolidated Appropriations Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-04-19T00:29:00-04:00
3153406 MARSHALL & POPP, LLC fa1e54b8-ff8d-40b4-b7d7-cce39bae3a33 Q1 MARSHALL & POPP, LLC 401105121 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2024 first_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development and distribution. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S.127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R.2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R.5378 - Lower Costs, More Transparency Act, and H.R.4366, Consolidated Appropriations Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. S.3558, Biosecure. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-04-19T00:31:09-04:00
3153410 MARSHALL & POPP, LLC 4a94a7e2-e06a-4db3-aaf0-f558883849f1 Q1 MARSHALL & POPP, LLC 401105121 SANOFI U.S. SERVICES, INC. 2024 first_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S.127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R.5378 - Lower Costs, More Transparency Act, and H.R. 4366, Consolidated Appropriations Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-04-19T00:32:55-04:00
3153872 MEHLMAN CONSULTING, INC. f5fac367-c07e-4f40-8281-5cb5cea7fa59 Q1 MEHLMAN CONSULTING, INC. 284950 AARP, INC. 2024 first_quarter PHA Issues related to the cost of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-04-19T09:29:19-04:00
3153927 NATIONAL GROCERS ASSOCIATION b5256b7f-df35-4462-8ac0-cbed5010e865 Q1 NATIONAL GROCERS ASSOCIATION 27924 NATIONAL GROCERS ASSOCIATION 2024 first_quarter PHA Protect Patient Access to Pharmacies Act Pharmacy Direct and Indirect Remuneration Fee Reform Pharmacy Benefit Manager Transparency Pharmacy Quality Measures Standardized pharmacy performance measures Any Willing Pharmacy Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   178466 0 0 2024-04-19T09:36:48-04:00
3154131 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 96e16f02-dcd0-494f-92f7-df5b0c77e032 Q1 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2024 first_quarter PHA Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA) Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   540662 0 0 2024-04-19T09:56:01-04:00
3154434 CARD & ASSOCIATES, LLC 68fda28d-d081-4aa0-9da3-f4bd896a9ba6 Q1 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2024 first_quarter PHA Monitor legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitor FY 2024 Appropriations Support access to telehealth Monitor and engage on EU digital regulatory policies Monitor international trade issues HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-04-19T10:20:42-04:00
3154436 FAEGRE DRINKER BIDDLE & REATH LLP 55abbb07-89dc-4b93-ae07-e7459fc3f865 Q1 FAEGRE DRINKER BIDDLE & REATH LLP 12631 VERDE ENVIRONMENTAL TECHNOLOGIES, INC. 2024 first_quarter PHA Drug safety. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 20000   0 0 2024-04-19T10:20:53-04:00
3154591 FAEGRE DRINKER BIDDLE & REATH LLP e9d00358-48c2-4d38-9f17-98022dd49acb Q1 FAEGRE DRINKER BIDDLE & REATH LLP 12631 ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP GLOBAL) 2024 first_quarter PHA Illicit prescription drug sales online; Rogue internet drug sellers; Dangers of counterfeit medicines; Risks of drug importation on patient safety; Domain name system accountability; S.3399, H.R. 6352 - Domain Reform for Unlawful Drug Sellers Act (DRUGS Act);S. 1843, H.R. 3429 - SHOPSAFE Act; S. 4858 - Cooper Davis Act. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-04-19T10:32:06-04:00
3154605 AKIN GUMP STRAUSS HAUER & FELD 947b6a69-1f4f-4f93-84d6-0d7fd41705a0 Q1 AKIN GUMP STRAUSS HAUER & FELD 682 CENTRIENT PHARMACEUTICALS LLC 2024 first_quarter PHA Issues related to onshoring supply chains and biomanufacturing of essential medicines to the United States. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-04-19T10:33:24-04:00
3154701 CARD & ASSOCIATES, LLC c14fc470-ecb6-4e67-8460-1d29ea521d9d Q1 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2024 first_quarter PHA Monitor legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitor FY 2024 Appropriations Support access to telehealth Monitor and engage on EU digital regulatory policies Monitor international trade issues HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-04-19T10:41:14-04:00
3154775 MEHLMAN CONSULTING, INC. 173df5e5-5a5a-4b63-9cf0-a774119bb567 Q1 MEHLMAN CONSULTING, INC. 284950 ASSOCIATION OF ACCESSIBLE MEDICINES 2024 first_quarter PHA Drug shortages. S. 775 - Increasing Transparency in Generic Drug Applications Act. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-04-19T10:47:32-04:00
3154826 NELSON MULLINS RILEY & SCARBOROUGH 11b170bd-e554-4691-86a6-ee42575f6879 Q1 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2024 first_quarter PHA 340B Drug Pricing Program, Patient Co-pays Legislation (H.R. 830), Medicare Coverage HOUSE OF REPRESENTATIVES 20000   0 0 2024-04-19T10:52:30-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 2723.744ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API